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435 Age at death of patients with cystic ﬁbrosis in South and
Mid Wales and the effect of treatment at a specialized centre:
2001–2009
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Historical data suggests increased survival in patients with cystic ﬁbrosis (CF)
receiving care at specialized centres. South and Mid Wales has a well-developed
network of care for children and young people with CF, encompassing both full
centre care and shared care with local CF clinics. Patients transfer to a full care
adult model at approximately 18 yrs of age.
We compared the age of death of adults with CF in South and Mid-Wales who
had received full CF centre care during childhood with those who had received CF
clinic shared care. Patients diagnosed with cystic ﬁbrosis after 18 yrs of age were
excluded from the analysis.
Between May 2001 and October 2009, the deaths of 42 adults with CF in South
and Mid Wales were notiﬁed. Fourteen (33%) patients received full care at a CF
centre while 28 (67%) received shared care at their local CF clinic. The mean age
at death was 30.4 years in patients who received full care compared to 26.8 years
in those receiving shared care (Diff 3.6 years; 95% CI −8.8 to 0.5; p = 0.08).
Although the difference in age at death between the two groups is not statistically
signiﬁcant, a 3.6 year difference in survival is likely to be clinically signiﬁcant,
suggesting that care provided at a specialized CF centre in childhood may confer a
survival advantage.
436 Cystic ﬁbrosis survival: the factors we can’t control
M. Pinto1, L. Pereira1, T. Rodrigues2, C. Barreto1. 1Hospital de Santa Maria,
Departamento da Crianc¸a e da Familia; Centro de Fibrose Quı´stica, Lisboa,
Portugal; 2Faculdade de Medicina Lisboa, Biomathematics Lab, Lisboa, Portugal
Introduction: Several factors have been associated with disease severity in Cystic
Fibrosis (CF) patients. Pancreatic insufﬁciency, elevated sweat chloride and the
presence of class I and II mutations are among them.
Objectives: To evaluate the differences in median survival between patients with
CF according to different pancreatic function, disease mutations and values of sweat
chloride test.
Methods: The Study was performed using data from clinical ﬁles. Survival
Statistical analysis was performed using Kaplan–Meyer survival curves and Cox’s
proportional Hazards Model using SPSS 16.0.
Results:We studied a total of 205 patients with CF covering 30 years. Data referring
pancreatic status was available in 156 patients of which 113 had insufﬁciency. In this
group the estimated median survival age was 26.5 years comparing to 41.4 years
for the all group (p< 0.005). The sweat chloride test, in a group of 144 patients,
was above 100 in 68% and under 100 in 32%. The mean survival age in the ﬁrst
group was 31.5 years and in the second group 41.1, comparing with an overall
mean of 37.8 years (p: 0.18). Considering only patients with a 20 years follow up,
the group above 100 have a mean survival age of 34.9 years and the other group
47.1 (p: 0.01). In patients in whom a speciﬁc mutation was identiﬁed, 27 had III,
IV or V mutations classes, with a median survival of 41.4 years and 103 patients
had mutations classiﬁed in class I or II with an estimated median survival age of
29.7 years (p: 0.17).
Conclusion: The survival in patients with CF could be associated with factors that
are patient’s characteristics. Their knowledge is a crucial point in the improvement
of survival.
437 Cystic ﬁbrosis in Portugal: a survival study
M. Pinto1, L. Pereira1, T. Rodrigues2, C. Barreto1. 1Hospital de Santa Maria,
Departamento da Crianc¸a e da Famı´lia, Lisboa, Portugal; 2Faculdade de Medicina
Lisboa, Biomathematics Lab, Lisboa, Portugal
Introduction: The progressive improvement of survival in patients with Cystic
Fibrosis, one reality nowadays, is one of the main goals of the management of
the disease and of the research that is being made in the different ﬁelds of this
condition.
Objectives: To determine the median survival age in patients with Cystic Fibrosis
followed in a Portuguese Center, covering the period 1969–2008.
Methods: A retrospective study was performed using data from clinical ﬁles.
Survival Statistical analysis was performed using Kaplan–Meyer survival curves
and Cox’s proportional Hazards Model using SPSS 16.0.
Results: We analyzed a total of 205 patients with the diagnosis of Cystic Fibrosis,
(55.1% females) covering a 30 years period. The median survival age in females
was 30.74 years (95% IC [20.1–41.34]) and 32.72 years (95% IC [26.4–38.9]) in
males, with an overall median of 30.74 years (95% IC [25.0–36.4]) (p: 0.386).
Considering 1999–2008 decade base we had an estimate death risk (Hazard Ratio:
10.41; 95% CI [1.34−]; p: 0.02) that was half the risk estimated for decade before
(HR: 20.01; 95% CI [2.69−] (p: 0.003). The probability of a child to survive
10 years was 78.4% in 1999 and 83.3% in 2008. In a child that is born in 2008 the
probability of surviving for 30 years is 49.3% in females and 50.5% in males.
Conclusion: The risk of death among CF patients has diminishing over the decades,
reﬂecting an improvement in survival as reported in other European Countries.
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A prospective study has been designed in order to evaluate the costs of treatment of
CF patients in Italy, since no pharmacoeconomic evaluation of this disease has ever
been performed in this country. The aim of the study is to assess the consumption
of resources (direct medical costs) for the treatment of CF patients afferent to the
Lombardia’s Regional Centre of CF, settled in Milan. Enrolment procedure was
completed in June 2009 and study completion is expected by June 2010.
No randomization has been performed; 165 patients have been enrolled by chrono-
logical admittance to the Centre and followed prospectively for 12 months with
no changes in the treatment procedures or number of visits. The 165 patients
(mean age 12.1; 51.5% female) were split into two groups stratifying by age:
Group I (55 patients 5 years − mean age 2.6; 45.5% female) and Group II
(110 patients >5 years − mean age 16.9; 54.5% female). In order to analyze the
cost of patients according to the disease severity, the algorithm of Liou (2001)
has been applied and likelihood of 5-years survival was calculated on the basis
of previously collected clinical data. This algorithm was applied only to Group-II
(5-years survivorship: Overall 89.9% [11.3–99.9%]; Female 88.2% [11.3–99.9%];
Male 92.0% [37.1–99.9%]), since FEV1 evaluation cannot be performed in small
children (Group I). By extending Liou’s algorithm, the data costs of the study
population will be transferred to the entire population (338 patients with age >5
years − mean age 16.1; 50.0% female; Overall 5-years survivorship 92.6% [9.3–
99.9%]) afferent to the Centre, giving a full description of the Centre costs.
